Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna’s Shot Sales, Canceled Contract Lead to Another Loss
Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled ...
Moderna price target lowered to $32 from $34 at BofA
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.
Moderna downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Moderna (MRNA) to Equal Weight from Overweight with a price target of $45, down from $111, post the Q4 report. The firm ...
ca.investing.com on MSN11h
Moderna has limited upside: Barclays
Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...
FierceBiotech4d
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
FiercePharma5d
Moderna trims digital team, lays off employees as chief information officer departs
Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...
Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
No, Moderna Did Not Create Its COVID Vaccine Two Years Before the Pandemic
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
Moderna Stock Rebounds Despite Vaccine Maker's Wider-Than-Expected Loss
Moderna shares fell 3% in premarket trading after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, ...